近日，天津市科技局公示2024年天津市创新联合体拟组建名单，天津市核酸疫苗及药物创新联合体获批组建。该联合体由天津经开区企业康希诺生物牵头，联合天津国际生物医药联合研究院、天津全和诚科技有限责任公司等多家经开区、天津市具有丰富核酸疫苗、药物领域领先技术的企业、高校及科研院所组建，将围绕天津市核酸产业领域，布局核酸疫苗、创新药物、器械、设备、原辅料、CMC、CRO、评价等核酸全产业链，加快构建核酸药物创新体系，搭建国内一流的核酸疫苗及药物创新技术平台，专注创新型核酸疫苗及药物管线开发，形成较成熟的核酸药物产业化落地模式及较好的区域示范带动作用。
Tianjin Municipal Science and Technology Bureau recently announced the List of Tianjin Municipal Innovation Consortia Proposed to be Established in 2024. Tianjin Nucleic Acid Vaccine and Drug Innovation Consortium was on the List. The consortium is led by TEDA-based CanSino Biologics and jointly established by the Tianjin International Joint Academy of Biomedicine, CosyChem Technology (Tianjin) Co., Ltd., and many other enterprises, universities, and research institutes from TEDA and Tianjin, with rich advanced technologies in nucleic acid vaccines and drugs. Centering on the nucleic acid industry in Tianjin, the consortium will focus on the entire nucleic acid industrial chain covering nucleic acid vaccines, innovative drugs, medical devices and equipment, raw materials, CMC, CRO, and evaluation, to accelerate the construction of an innovative nucleic acid drug system and create China’s top-tier platform for nucleic acid vaccine and drug innovation. It plans to take the R&D of innovative nucleic acid vaccine and drug pipelines as a key focus to create a mature model for implementing the industrialization of nucleic acid drugs and provide a strong regional demonstration effect.
核酸药物作为生物医药未来产业，是天津先进制造业和新质生产力的重要着力点。2022年，天津经开区管委会联合区内核酸企业发起成立天津（经开区）核酸产业联盟，目前联盟成员单位37家，涵盖核酸药物开发、生产、服务外包、装备配套等产业链相关企业，建立起政府、重点高校、国有资本平台、领军企业“共商、共建、共享、共谋”的运营机制，进一步加速了核酸药物产业在经开区的发展和壮大。
As a future-oriented biopharmaceutical sector, nucleic acid drugs are a propellor for promoting Tianjin’s advanced manufacturing industry and new quality productive forces. In 2022, TEDA Administrative Commission, together with local nucleic acid enterprises, initiated the Tianjin (TEDA) Nucleic Acid Industry Alliance. The alliance now includes 37 member organizations, covering areas such as the R&D, production, service outsourcing, and auxiliary equipment of nucleic acid drug along the industrial chain. It has established an operating mechanism involving the government, major universities, state-owned capital platforms, and leading enterprises, to achieve shared benefits through consultation, collaboration and discussion, further accelerating the development and expansion of the nucleic acid drug industry in TEDA.
